Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon브라질 아마존에서 SARS-CoV-2 Mu 변종(B.1.621) 지역사회 전파에 대한 능동적 감시 및 조기 탐지Article Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Active surveillance All participants Amino acid amino acid substitution Antigen assist Asymptomatic B.1.621 blood sample Blood samples Brazilian Amazon Chain Reaction circulating city collected Community community transmission Contact tracing country COVID-19 patient Diagnosis diagnostic test ELISA testing Emergency epidemiological data followed by genomic genomic sequencing Genomic surveillance highlight household contacts identify IgA IgG IgG levels IgM antibody IgM antibody levels individual infected individual information mild symptoms Mu variant nasopharyngeal swabs one patient ORF1a ORF7a outpatients Participants polymerase chain reaction Porto prospective cohort Rapid diagnostic test reference sequence Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sequenced specimen Surveillance Swab tested Travel variant virus viruses [DOI] 10.1002/jmv.27686 PMC 바로가기 [Article Type] Article
Positivity rates of SAR-CoV-2 infection in orthodontic patients at the orthodontic clinic, University of Illinois ChicagoUniversity of Illinois Chicago 교정 진료소 교정 환자의 SAR-CoV-2 감염 양성률Article Published on 2022-06-232022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 치료기술, [키워드] age All participant All participants Asymptomatic average Chain Reaction Chicago collected Community Complete COVID-19 COVID-19 infection COVID-19 transmission COVID-19 vaccination detect females Frequency healthcare providers impacted increased risk Infection information Local male nine orthodontic participant Participants participated Patient patients PCR polymerase chain polymerase chain reaction positive potential risk potential transmission risk Saliva SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection Sex tested Treatment university vaccination Vaccination Status were recorded [DOI] 10.1371/journal.pone.0270311 PMC 바로가기 [Article Type] Article
Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial호흡기 감염 감소를 위한 아스토드리머 나트륨 항바이러스 비강 스프레이는 무작위 대조 시험에서 안전하고 내약성이 우수합니다.Randomized Controlled Trial Published on 2022-06-172022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료제, [키워드] absorbed Absorption Administered administration adverse event All participants Antiviral applied clinical clinical investigation clinical trial clinically Cohort Community community acquired dendrimer double-blinded Effects examination finding examination findings exploratory exposure to followed by four times daily Frequency healthy volunteer help in vitro Infection initial intensity Intensive Mild nasal Nasal cavity nasal mucosa Nasal spray New nostril occurred other respiratory virus Other respiratory viruses participant Placebo placebo-controlled primary endpoint product Randomized Randomized controlled trial receiving reduce reducing Registered registry respiratory infection respiratory virus Respiratory virus infections respiratory viruses Safe safety population SARS-CoV-2 serious AEs severity shown sodium spray Spread systemically TEAE TEAEs Tolerability Treatment Trial registration utility vaginal mucosa Viral load virucidal Withdrawal [DOI] 10.1038/s41598-022-14601-3 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial6~17세 어린이 대상 ChAdOx1 nCoV-19(AZD1222) 백신의 안전성 및 면역원성: 2상 단일 맹검, 무작위, 대조 시험인 COV006의 예비 보고서Clinical Trial Published on 2022-06-112022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI administration Adults adverse event adverse events age All participants anti-SARS-CoV-2 IgG antibody Antibody titre antibody titres arbitrary unit assigned AstraZeneca AZD1222 baseline capsular Cellular responses ChAdOx1 ChAdOx1 nCoV-19 children chronic respiratory conditions Concentration Controlled trial COVID-19 COVID-19 vaccine COVID-19 vaccines Cutoff Department dose doses Efficacy enrolled Fever first dose first vaccination four group four groups geometric geometric mean geometric mean ratios Geometric means group half-maximal inhibitory concentration Humoral response humoral responses immune response immune responses immunogenic immunogenicity in some intramuscular dose introduced investigators ISRCTN Laboratory laboratory-confirmed Laboratory-confirmed COVID-19 Local nucleocapsid protein Pain and tenderness participant Participants peaked Phase 2 phase 3 study preliminary report Primary outcome prime and boost raised randomised Randomly receive receiving recruitment Registered remained reported resolved respiratory response Safety safety population SARS-CoV-2 second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events seronegative seronegative participant seronegative participants seropositive serostatus single-blind stratified study drug study groups tenderness Tolerability treatment allocation Trial vaccination Vaccine Viral viral particle were recorded [DOI] 10.1016/S0140-6736(22)00770-X PMC 바로가기 [Article Type] Clinical Trial
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases면역 매개 염증성 질환 환자에서 SARS-CoV-2 mRNA 백신에 대한 면역 약화 가속화Observational Study Published on 2022-06-082022-09-11 Journal: JCI Insight [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] Adaptive immunity Adult patients All participants ankylosing spondylitis anti-TNF Arthritis attrition Autoimmune diseases azathioprine COVID-19 COVID-19 vaccination declining disease donation dose Efficacy examined force greater healthy control healthy controls Immune-mediated inflammatory disease Immune-mediated inflammatory diseases Immunity immunogenicity immunology Immunosuppressant immunosuppressants immunosuppressive therapies Immunotherapy Inflammatory bowel disease Inflammatory diseases information Juan methotrexate mRNA vaccine neutralization Observational cohort study omicron Participants Patient rapid response rheumatoid arthritis SARS-CoV-2 SARS-CoV-2 variants Speck spondylitis subjects Support T cell T cell response Task Force Treatment undetectable Vaccine variants variants of concern [DOI] 10.1172/jci.insight.159721 PMC 바로가기 [Article Type] Observational Study
Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults혈액 단핵 세포의 산화 스트레스와 내인성 DNA 손상은 노인에서 예방 접종 후 항 SARS-CoV-2 항체 역가를 예측할 수 있습니다Article Published on 2022-06-012022-09-11 Journal: Biochimica et biophysica acta. Molecular basis of [Category] COVID19(2023년), SARS, 치료기술, [키워드] age All participants anti-S anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody Anti-spike antibodies antibody Biomarker Biomarkers Blood BNT162b2 circulating correlated DNA DNA damage DNA damage response double-strand break DSBs Efficacy Efficiency first dose genomic humoral immune response Humoral response humoral responses Hypothesis IgG antibodies Immune cell immune cells immune senescence increase in Increased individual inverse correlation mononuclear cell mRNA vaccination neutralizing capacity Older oxidative oxidative stress Participants Peripheral blood Peripheral blood mononuclear cells pre-vaccination predict SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 vaccination second dose Stress tested titers vaccination Vaccine vaccine efficacy [DOI] 10.1016/j.bbadis.2022.166393 PMC 바로가기 [Article Type] Article
Concordance in RT-PCR detection of SARS-CoV-2 between samples preserved in viral and bacterial transport medium바이러스 및 박테리아 수송 배지에 보존된 샘플 간의 SARS-CoV-2 RT-PCR 검출 일치Article Published on 2022-06-012022-09-11 Journal: Journal of virological methods [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] All participants analyzed Bacteria Bacterial calculated collected Community Concordance Ct values cycle threshold determine Diagnostic method Glucose Glycerin in viral independent independent of longitudinal cohort study medium nasal nasal swab nasal swabs nasopharyngeal Nasopharyngeal swab NP swab NP swabs ORF1 ORF1ab participant Pathogens preserved real time respiratory pathogen respiratory symptoms RT-PCR RT-PCR detection Sample SARS-CoV-2 SARS-CoV-2 detection SARS-CoV-2 infections skim milk specimen statistically Swab swabs targets Transport Transport media transport medium tryptone Viral transport medium VTM was used while [DOI] 10.1016/j.jviromet.2022.114522 PMC 바로가기 [Article Type] Article
Rationale and Design for the LOnger-term effects of SARS-CoV-2 INfection on blood Vessels And blood pRessure (LOCHINVAR): an observational phenotyping study혈관 및 혈압(LOCHINVAR)에 대한 SARS-CoV-2 감염의 장기 효과에 대한 이론적 근거 및 설계: 관찰 표현형 연구Observational Study Published on 2022-06-012022-09-11 Journal: Open Heart [Category] COVID19(2023년), SARS, 임상, 치료기술, [키워드] All participant All participants All study participants angiotensin approved baseline Biomarkers Blood blood pressure blood sample Blood samples blood vessels brachial calculated Confirmed COVID-19 infection consequence Control controls COVID-19 COVID-19 infection detect discharge Effect Elizabeth endothelial Endothelium Ethics ethics committee Evidence evidence of Hospital admission hypertension Immune status include individual Interaction International mean difference medication Myocardial infarction normal blood pressure participant Patient peer-reviewed pilot study Primary outcome protocol provided rationale recruited registration number Renin renin-angiotensin system Research Research design Research Ethics Research Ethics Committee Sample Sample size SARS-CoV-2 SARS-COV-2 infection SBP stroke Study participants submitted systolic undergo university Urine Vascular vascular inflammation West with COVID-19 written Informed Consent [DOI] 10.1136/openhrt-2022-002057 PMC 바로가기 [Article Type] Observational Study
Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 – A Comprehensive Analysis경증 COVID-19 이후 최대 1년까지 SARS-CoV-2 WT 및 변이체에 대한 B 세포 반응의 적합성 - 종합 분석Article Published on 2022-05-022022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Affinity maturation All participants Alpha Anti-RBD antibodies antibodies antibody Antibody Response Antibody responses Antibody titer Antibody titers Antigen antigen-specific memory B cells assays avidity B-cell binding binding antibodies binding antibody Comprehensive correlated COVID-19 declined Delta delta variant domain ELISA ELISPOT evaluate fitness Gamma IgA IgG memory B memory B cell memory B cells memory B-cell Mild N protein neutralization Neutralizing Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers Neutralizing titer neutralizing titers nucleocapsid participant plasmablast plasmablast responses plasmablasts post infection predicted Protein remained response SARS-CoV-2 SARS-CoV-2 specific memory B cells SARS-CoV-2 WT significantly increased symptomatic thiocyanate titers variant variants variants of concern waned were assessed were measured wild-type Year [DOI] 10.3389/fimmu.2022.841009 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study건강한 성인에서 AS03 보조제 SARS-CoV-2 재조합 단백질 백신(CoV2 preS dTM)의 안전성 및 면역원성: 2상, 무작위, 용량 찾기, 다기관 연구의 중간 결과Clinical Trial Published on 2022-05-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI abstinence adjuvants Adults adverse event adverse events Adverse reaction Adverse reactions age All participant All participants antibody Antibody titre Antigen AS03 assessments assigned authority baseline booster vaccination candidate vaccine Chemotherapy childbearing potential clinical development Clinical research clinical trial Cohort Contraception COVID-19 vaccine D614G variant development dose effective Endpoint enrolled evaluated expected fixed Frequency geometric mean geometric mean titre GMT GMT ratio GMTs groups healthy High dose High-dose high-dose group Immunocompromised immunogenicity increase in increased risk injection injection site Injections intensity interim results investigator investigators involved Laboratory lactating low dose low-dose medical condition Medical conditions medium medium dose Mild mild to moderate moderate multicentre Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres occurred Older Older adults Organ transplant outcome outcome assessor outcome assessors parallel-group participant Participants Phase 2 Phase 3 positive prefusion pregnant primary immunogenicity progression proportion Protein protocol provided pseudovirus neutralisation assay randomised Randomly reactogenicity receive Registered reported Research research and development responses robust Safety safety analysis safety endpoints safety profile Sanofi Pasteur SARS-CoV-2 second dose second vaccination selected Serious Adverse Event Serious Adverse Events serodiagnostic Seven severe COVID-19 Stratification study period supported systemic test result titre titres Treatment treatment group treatment groups Trial USA vaccination Vaccine was done were excluded were measured yes or no [DOI] 10.1016/S1473-3099(21)00764-7 PMC 바로가기 [Article Type] Clinical Trial